Previous 10 | Next 10 |
2023-03-20 08:55:19 ET Athenex press release ( NASDAQ: ATNX ): Q4 GAAP EPS of -$4.28. Revenue of $25.06M (+39.8% Y/Y). Cash, cash equivalents, and restricted cash balance of $35.6 million For further details see: Athenex GAAP EPS of -$4.28, revenue of $25...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...
Athenex ( NASDAQ: ATNX ) on Tuesday said it will effect a 1-for-20 reverse stock split of its issued common stock. Beginning February 15, 2023, the company's common stock will trade on a split-adjusted basis. Athenex's board implemented the reverse stock split with the obj...
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 r...
Main Tips for Buying Penny Stocks Right Now Penny stocks have been a popular investment option for many years, offering the potential for high returns at a relatively low cost. With the stock market constantly fluctuating, penny stocks can offer a great opportunity for those looking to ma...
The definition of penny stocks typically includes small companies and cheap stocks trading for less than $5 per share. But if you’ve been trading for more than a month, you already know that it is just the tip of the iceberg regarding these low-priced stocks. In most cases, especia...
The UK's Medicines and Healthcare Products Regulatory Agency has declined to approve Athenex's ( NASDAQ: ATNX ) oral paclitaxel for metastatic breast cancer . The rejection was due to chemistry, manufacturing, and control ("CMC") issues, and not due to efficacy or safety ...
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issues Athenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study an...
Stocks To Watch Trading For Pennies Right Now; Are They Worth The Risk? The definition of penny stocks typically includes a blanket description for stocks under $5. But ask most retail traders, and they’ve got a slightly different iteration of the term. In many cases, penny stocks ...
Top Tips to Use for Finding Penny Stocks to Buy Identifying penny stocks with high potential requires a combination of research, due diligence, and risk management. The key is to look for penny stocks that have strong fundamentals, are trading at a low price, and have the potential to gen...
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...